Molecular immunologic strategies to identify antigens and b-cell responses unique to multiple sclerosis.
Identification of the causative agent of multiple sclerosis (MS) has long eluded investigators and has become the "Holy Grail" of researchers in the field. The immune response in cerebrospinal fluid of patients with MS, indicated by an increased IgG level and the presence of specific oligoclonal bands after electrophoresis, strongly parallels that found in various infectious diseases of the central nervous system. To understand the nature of B-lymphocyte activation in MS, 4 laboratories studied the antigen-binding regions of antibodies found in MS brain demyelinative plaques and cerebrospinal fluid. Each analysis revealed (1) limited germline expression, results not expected for a random bystander response; (2) features consistent with a specific antigen-targeted process; and (3) the clonal expansion of populations of B lymphocytes in MS. The screening of libraries expressing protein products derived from chronic MS plaque messenger RNA with antibodies purified from plaques, cerebrospinal fluid, or serum of patients with MS has thus far not revealed the antigenic target(s) of the MS antibody response. Because putative MS antigens could be in low abundance, the screening of large libraries of random peptides expressed on phage surfaces might offer an alternative approach to identify peptide sequences recognized by MS antibodies. New sophisticated molecular immunologic techniques described herein should enhance our ability to identify putative antigen(s) targets in MS.
Gilden
D H
DH
Department of Neurology, University of Colorado Health Sciences Center, 4200 E Ninth Ave, Mail Stop B182, Denver, CO 80262, USA. don.gilden@uchsc.edu
Burgoon
M P
MP
Kleinschmidt-DeMasters
B K
BK
Williamson
R A
RA
Ghausi
O
O
Burton
D R
DR
Owens
G P
GP
D000911:Antibodies, Monoclonal / Q000235:genetics; D000914:Antibodies, Viral / Q000276:immunology; D000915:Antibody Affinity / Q000276:immunology; D015703:Antigens, CD / Q000134:cerebrospinal fluid / Q000235:genetics* / Q000276:immunology*; D001402:B-Lymphocytes / Q000276:immunology*; D001921:Brain / Q000276:immunology*; D002908:Chronic Disease; D003001:Cloning, Molecular / Q000379:methods; D018076:DNA, Complementary / Q000235:genetics / Q000276:immunology; D004274:DNA, Recombinant; D018450:Disease Progression; D000939:Epitopes; D005240:Feasibility Studies; D015723:Gene Library; D006801:Humans; D007136:Immunoglobulins / Q000134:cerebrospinal fluid / Q000235:genetics / Q000276:immunology*; D009103:Multiple Sclerosis / Q000134:cerebrospinal fluid / Q000235:genetics* / Q000276:immunology*; D019151:Peptide Library; D011110:Polymorphism, Genetic / Q000235:genetics / Q000276:immunology; D012333:RNA, Messenger / Q000235:genetics / Q000276:immunology
D000911:Antibodies, Monoclonal; D000914:Antibodies, Viral; D015703:Antigens, CD; D018076:DNA, Complementary; D004274:DNA, Recombinant; D000939:Epitopes; D007136:Immunoglobulins; D019151:Peptide Library; D012333:RNA, Messenger